Previous 10 | Next 10 |
NexImmune ( NASDAQ: NEXI ) stock jumped 23% postmarket on Thursday after the firm received investigational new drug clearance by FDA for its first cellular therapy candidate for solid tumors. NEXI-003, an autologous antigen-specific T cell product, is being developed for p...
First IND for NexImmune’s AIM nanoparticle platform in solid tumors IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-r...
Shares of immune biopharma NexImmune have cratered 90% from their IPO pricing as early returns from two Phase 1/2 trials have failed to impress. In theory, the output from its AIM platform should improve upon CAR T therapies, as they are more specific and thus should be more effective...
Gainers: TherapeuticsMD (TXMD) +361%. JanOne (JAN) +70%. Houston American Energy (HUSA) +57%. CatchMark Timber Trust (CTT) +44%. Mullen Automotive (MULN) +43%. Gogoro (GGR) +37%. BlackSky Technology (BKSY) +32%. Cassava Sciences (SAVA) +25%. MicroStrategy (MSTR) +24%. NexImmune (NEXI) +23%. L...
Neximmune press release (NASDAQ:NEXI): Q1 GAAP EPS of -$0.66 beats by $0.05. Based upon current operating plans, the company expects that its existing cash, cash equivalents and marketable securities of $65M will enable the Company to fund its operating and capital expenditure requirements in...
Clinical data updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 2H2022 Investigational New Drug (IND) submission for NEXI-003, the Company’s first product for solid tumors, planned for 1H2022 Plans to report ad...
A JDRF funded grant will be used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI...
GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announ...
GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today anno...
Gainers: Clarus Therapeutics Holdings (CRXT) +87%. Winc (WBEV) +27%. AlloVir (ALVR) +26%. NexImmune (NEXI) +24%. Charah Solutions (CHRA) +22%. Target Hospitality (TH) +20%. Phio Pharmaceuticals (PHIO) +20%. Healthcare Services Group (HCSG) +19%. CEL-SCI (CVM) +18%. Biophytis (BPTS) +17%. Lose...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...